Literature DB >> 9343254

Susceptibility of human immunodeficiency virus type 1 group O isolates to antiretroviral agents: in vitro phenotypic and genotypic analyses.

D Descamps1, G Collin, F Letourneur, C Apetrei, F Damond, I Loussert-Ajaka, F Simon, S Saragosti, F Brun-Vézinet.   

Abstract

We investigated the phenotypic and genotypic susceptibility of 11 human immunodeficiency virus type 1 (HIV-1) group O strains to nucleoside and nonnucleoside reverse transcriptase (RT) inhibitors and protease inhibitors in vitro. Phenotypic susceptibility was determined by using a standardized in vitro assay of RT inhibition, taking into account the replication kinetics of each strain. HIV-1 group M and HIV-2 isolates were used as references. DNA from cocultured peripheral blood mononuclear cells was amplified by using pol-specific group O primers and cloned for sequencing. Group O isolates were highly sensitive to nucleoside inhibitors, but six isolates were naturally highly resistant to all of the nonnucleoside RT inhibitors tested. Phylogenetic analysis of the pol gene showed that these isolates formed a separate cluster within group O, and genotypic analysis revealed a tyrosine-to-cysteine substitution at residue 181. Differences in susceptibility to saquinavir and ritonavir (RTV) were not significant between group O and group M isolates, although the 50% inhibitory concentration of RTV for group O isolates was higher than that for the HIV-1 subtype B strains. The study of HIV-1 group O susceptibility to antiretroviral drugs revealed that the viruses tested had specific phenotypic characteristics contrasting with the group M phenotypic expression.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9343254      PMCID: PMC192360     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  24 in total

Review 1.  Resistance of clinical isolates of human immunodeficiency virus to antiretroviral agents.

Authors:  D D Richman
Journal:  Antimicrob Agents Chemother       Date:  1993-06       Impact factor: 5.191

2.  Mutational trends in V3 loop protein sequences observed in different genetic lineages of human immunodeficiency virus type 1.

Authors:  B T Korber; K MacInnes; R F Smith; G Myers
Journal:  J Virol       Date:  1994-10       Impact factor: 5.103

3.  Isolation and envelope sequence of a highly divergent HIV-1 isolate: definition of a new HIV-1 group.

Authors:  P Charneau; A M Borman; C Quillent; D Guétard; S Chamaret; J Cohen; G Rémy; L Montagnier; F Clavel
Journal:  Virology       Date:  1994-11-15       Impact factor: 3.616

4.  Genomic cloning and complete sequence analysis of a highly divergent African human immunodeficiency virus isolate.

Authors:  M Vanden Haesevelde; J L Decourt; R J De Leys; B Vanderborght; G van der Groen; H van Heuverswijn; E Saman
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

5.  A new subtype of human immunodeficiency virus type 1 (MVP-5180) from Cameroon.

Authors:  L G Gürtler; P H Hauser; J Eberle; A von Brunn; S Knapp; L Zekeng; J M Tsague; L Kaptue
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

6.  Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy.

Authors:  D D Richman; D Havlir; J Corbeil; D Looney; C Ignacio; S A Spector; J Sullivan; S Cheeseman; K Barringer; D Pauletti
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

7.  HIV-1 sensitivity to zidovudine: a consensus culture technique validated by genotypic analysis of the reverse transcriptase.

Authors:  F Brun-Vézinet; D Ingrand; L Deforges; K Gochi; F Ferchal; M P Schmitt; M Jung; B Masquelier; J Aubert; C Buffet-Janvresse
Journal:  J Virol Methods       Date:  1992-05       Impact factor: 2.014

8.  Signature pattern analysis: a method for assessing viral sequence relatedness.

Authors:  B Korber; G Myers
Journal:  AIDS Res Hum Retroviruses       Date:  1992-09       Impact factor: 2.205

9.  HIV-1/HIV-2 seronegativity in HIV-1 subtype O infected patients.

Authors:  I Loussert-Ajaka; T D Ly; M L Chaix; D Ingrand; S Saragosti; A M Couroucé; F Brun-Vézinet; F Simon
Journal:  Lancet       Date:  1994-06-04       Impact factor: 79.321

Review 10.  Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase. Implications for mechanisms of drug inhibition and resistance.

Authors:  C Tantillo; J Ding; A Jacobo-Molina; R G Nanni; P L Boyer; S H Hughes; R Pauwels; K Andries; P A Janssen; E Arnold
Journal:  J Mol Biol       Date:  1994-10-28       Impact factor: 5.469

View more
  50 in total

1.  Quantitation of human immunodeficiency virus type 1 group O load in plasma by measuring reverse transcriptase activity.

Authors:  J G García Lerma; V Soriano; A Mas; M E Quiñones-Mateu; E J Arts; W Heneine
Journal:  J Clin Microbiol       Date:  2000-01       Impact factor: 5.948

2.  Development and evaluation of a DNA enzyme immunoassay method for env genotyping of subtypes A through G of human immunodeficiency virus type 1 group M, with discrimination of the circulating recombinant forms CRF01_AE and CRF02_AG.

Authors:  Jean-Christophe Plantier; Laurence Vergne; Florence Damond; Souleymane MBoup; Eitel MPoudi-NGole; Laurence Buzelay; Isabelle Farfara; Denys Brand; Martine Peeters; Françoise Brun-Vézinet; Eric Delaporte; Francis Barin
Journal:  J Clin Microbiol       Date:  2002-03       Impact factor: 5.948

3.  A Guide to HIV-1 Reverse Transcriptase and Protease Sequencing for Drug Resistance Studies.

Authors:  Robert W Shafer; Kathryn Dupnik; Mark A Winters; Susan H Eshleman
Journal:  HIV Seq Compend       Date:  2001

4.  Baseline genotypic and phenotypic susceptibilities of HIV-1 group O to enfuvirtide.

Authors:  Agnès Depatureaux; Charlotte Charpentier; Gilles Collin; Marie Leoz; Diane Descamps; Aurélia Vessière; Florence Damond; Dominique Rousset; Françoise Brun-Vézinet; Jean-Christophe Plantier
Journal:  Antimicrob Agents Chemother       Date:  2010-06-14       Impact factor: 5.191

Review 5.  NeuroAIDS in Africa.

Authors:  Kevin Robertson; Jeff Liner; James Hakim; Jean-Louis Sankalé; Igor Grant; Scott Letendre; David Clifford; Amadou Gallo Diop; Assan Jaye; Georgette Kanmogne; Alfred Njamnshi; T Dianne Langford; Tufa Gemechu Weyessa; Charles Wood; Mwanza Banda; Mina Hosseinipour; Ned Sacktor; Noeline Nakasuja; Paul Bangirana; Robert Paul; John Joska; Joseph Wong; Michael Boivin; Penny Holding; Betsy Kammerer; Annelies Van Rie; Prudence Ive; Avindra Nath; Kathy Lawler; Clement Adebamowo; Walter Royal; Jeymohan Joseph
Journal:  J Neurovirol       Date:  2010-05       Impact factor: 2.643

6.  HIV-1 Group O Genotypes and Phenotypes: Relationship to Fitness and Susceptibility to Antiretroviral Drugs.

Authors:  Denis M Tebit; Hamish Patel; Annette Ratcliff; Elodie Alessandri; Joseph Liu; Crystal Carpenter; Jean-Christophe Plantier; Eric J Arts
Journal:  AIDS Res Hum Retroviruses       Date:  2016-03-16       Impact factor: 2.205

Review 7.  Human immunodeficiency virus type 1 subtype distribution in the worldwide epidemic: pathogenetic and therapeutic implications.

Authors:  L Buonaguro; M L Tornesello; F M Buonaguro
Journal:  J Virol       Date:  2007-07-18       Impact factor: 5.103

8.  The Genetic Basis of HIV-1 Resistance to Reverse Transcriptase and Protease Inhibitors.

Authors:  Robert W Shafer; Rami Kantor; Matthew J Gonzales
Journal:  AIDS Rev       Date:  2000       Impact factor: 2.500

Review 9.  The challenge of HIV-1 subtype diversity.

Authors:  Barbara S Taylor; Magdalena E Sobieszczyk; Francine E McCutchan; Scott M Hammer
Journal:  N Engl J Med       Date:  2008-04-10       Impact factor: 91.245

10.  A Multiplex PCR Approach for Detecting Dual Infections and Recombinants Involving Major HIV Variants.

Authors:  Pierre Cappy; Fabienne De Oliveira; Marie Gueudin; Elodie Alessandri-Gradt; Jean-Christophe Plantier
Journal:  J Clin Microbiol       Date:  2016-02-24       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.